Role of Vitamin D Supplementation in Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Inclusion Criteria:
- Written informed consent
- Either sex between 19-50 years
- First episode schizophrenia with illness (< 7 years) receiving inpatient treatment
- Serum (25) OH D below 30 ng/ml
Exclusion Criteria:
- Presence of co-morbid psychiatric disorder
- History of substance use meeting dependence criteria excluding caffeine
- Co-morbid medical illness or medications known to affect vitamin D e.g. Hypothyroidism, Arthritis, Osteoporosis, Rickets, End Stage Renal Disease, Malabsorption Syndromes, Corticosteroid therapy
- Patients already on Vitamin D supplementation
- Patients with BMI more than 30kg/m² & women who have reached menopause as they have higher dietary requirements
Sites / Locations
- Central Institute of Psychiatry
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Antipsychotic and Vitamin D3
Antipsychotic and B Complex
Subjects randomised to vitamin D3 arm will receive a tablet containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
Subjects randomised to the B Complex arm will receive a tablet of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team